How to Read Peptide Research Without Falling for Marketing

Almost nobody selling peptides makes claims out of thin air. They cite papers. The papers are usually real. The problem is what the papers are — and the gap between what they measured and what the headline implies. This guide gives you five questions that close that gap.

Question 1: Who or what was studied?#

Start here, always. There are three broad answers, and they are not interchangeable:

• Cells in a dish (in vitro). Useful for mechanism. Tells you nothing about what happens in a body with a liver, kidneys, an immune system and enzymes that destroy peptides in minutes.
• Animals (in vivo, preclinical). Usually rats or mice, young and healthy, injured on purpose in a standardised way. Essential for early safety and biology. Poorly predictive of human efficacy: a review of highly cited animal studies found only about a third translated to human randomised trials, and about one in ten to an approved intervention^[5].
• Humans. Then ask: how many, how old, how healthy, how similar to you, and for how long?

Worked example — BPC-157. Search the literature and you find hundreds of papers, overwhelmingly positive, describing faster healing of tendon, muscle, ligament, gut and vessels. Read the methods and nearly all are rats. Reviewers noting this a decade ago called for human trials^[1]; controlled human efficacy trials still have not appeared. The honest description is not "well-studied" but "extensively studied in rodents".

Question 2: Was there a control group — and was it fair?#

An uncontrolled study observes people who took something and reports what happened. It cannot separate the treatment from:

• Time. Most injuries heal, most symptoms fluctuate, most people who start a treatment do so when things are at their worst (regression to the mean).
• Expectation. Placebo effects on subjective outcomes — pain, energy, libido, mood — are large and reliable.
• Selection. People who stick with a treatment long enough to be reported on are not a random sample.

Randomised, blinded, placebo-controlled trials exist to remove those confounders. Case reports, case series, open-label pilots and clinic testimonials do not, and no number of them adds up to a controlled trial.

Question 3: What was measured — a mechanism or an outcome?#

This is where most peptide marketing lives. A mechanism is a biological effect along the way: increased growth hormone, more angiogenesis, changed gene expression. An outcome is something a person would notice or a clinician would treat: more muscle, faster return to sport, fewer heart attacks.

Worked example — CJC-1295. The best human study of CJC-1295 is a real randomised, placebo-controlled trial. It showed that the drug raises growth hormone and IGF-1 for a week or more^[2]. That is a mechanism, cleanly demonstrated. It measured no body composition, no strength, no recovery, no aging endpoint. Every claim that CJC-1295 "builds lean muscle" or "burns fat" is an inference from that mechanism, not a finding.

Contrast SELECT, the semaglutide cardiovascular trial: 17,604 people, randomised, blinded, followed for years, primary endpoint heart attack, stroke or cardiovascular death^[4]. That is an outcome trial. The difference between the two studies is not that one is "positive" and the other "negative" — both are positive — but that only one answers a question a patient would ask.

Question 4: How big is the effect, and how sure are we?#

"Statistically significant" means the result is unlikely to be chance under the study's assumptions. It does not mean the effect is large, or that it matters. Look for:

• The absolute difference between groups (15% weight loss vs 2.4%, not "significantly more").
• The confidence interval — a wide interval that barely excludes zero is fragile.
• Whether the outcome was prespecified as primary, or fished from a list of twenty secondary measures.
• Whether a subjective endpoint (a questionnaire) was used where an objective one was possible.

Small trials with many endpoints and flexible analysis produce false positives at rates that surprise even researchers. If a paper's abstract highlights a secondary outcome, find out what happened to the primary one.

Question 5: Who paid, and who replicated?#

Industry funding does not make a result wrong. Most drug trials are industry-funded, including the incretin trials above. But it does mean the study was designed by people with a stake in the answer, and it raises the value of independent replication.

Worked example — collagen peptides. The skin-elasticity trial most often cited^[3] is a genuine randomised placebo-controlled study. It is also small (69 women), short (8 weeks), uses instrumental rather than clinical endpoints, and was funded by the ingredient manufacturer, as were most trials that followed. That is why the collagen evidence is graded promising — real, replicated across several trials, but not yet independent or long enough for established.

The other side of this coin is concentration: a body of literature that comes from one group, in one place, with one set of methods. Independent replication is what separates a research programme from a research finding. When you see "over 100 studies show…", ask how many laboratories.

The pattern behind most misleading claims#

Put the five questions together and a small number of moves account for most bad peptide content:

Using this on our own pages#

Every article on this site states its evidence level and regulatory status separately, lists study type for every reference, and shows sample size, population, primary result and limitations in expandable study details. If you catch us breaking one of these rules, that is a correction — tell us.

Where to go next#

• What are peptides? — the definitional groundwork.
• FDA-approved, off-label, investigational and unapproved peptides — regulatory categories, and why "not approved" is not one thing.
• Evidence levels explained — how we translate these questions into grades.